BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, Saposnik G, Sood MM, Molnar AO, Perl J, Wald RM, Silver S, Wald R. Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology 2017;33:737-46. [DOI: 10.1016/j.cjca.2017.02.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Piccoli GB, Nielsen L, Gendrot L, Fois A, Cataldo E, Cabiddu G. Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status. J Clin Med 2018;7:E331. [PMID: 30297628 DOI: 10.3390/jcm7100331] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
2 Kozieł M, Potpara TS, Lip GYH. Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. Res Pract Thromb Haemost 2020;4:357-65. [PMID: 32211570 DOI: 10.1002/rth2.12319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vio R, Proietti R, Rigato M, Calò LA. Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. Pharmaceuticals (Basel) 2021;14:279. [PMID: 33808739 DOI: 10.3390/ph14030279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Blum D, Beaubien-Souligny W, Battistella M, Tseng E, Harel Z, Nijjar J, Nazvitch E, Silver SA, Wald R. Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. Kidney Int Rep 2020;5:159-64. [PMID: 32043029 DOI: 10.1016/j.ekir.2019.10.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hu A, Niu J, Winkelmayer WC. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. Semin Nephrol 2018;38:618-28. [PMID: 30413255 DOI: 10.1016/j.semnephrol.2018.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
6 Alshogran OY. Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Curr Drug Metab 2019;20:633-45. [PMID: 31267868 DOI: 10.2174/1389200220666190701095807] [Reference Citation Analysis]
7 Starr JA, Pinner NA, Mannis M, Stuart MK. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Ann Pharmacother 2021;:10600280211040093. [PMID: 34459281 DOI: 10.1177/10600280211040093] [Reference Citation Analysis]
8 Jegatheswaran J, Hundemer GL, Massicotte-Azarniouch D, Sood MM. Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. Can J Cardiol 2019;35:1241-55. [PMID: 31472820 DOI: 10.1016/j.cjca.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khou V, De La Mata NL, Kelly PJ, Masson P, O'Lone E, Morton RL, Webster AC. Epidemiology of cardiovascular death in kidney failure: An Australian and New Zealand cohort study using data linkage. Nephrology (Carlton) 2022. [PMID: 35001453 DOI: 10.1111/nep.14020] [Reference Citation Analysis]
10 Samanta R, Chan C, Chauhan VS. Arrhythmias and Sudden Cardiac Death in End Stage Renal Disease: Epidemiology, Risk Factors, and Management. Canadian Journal of Cardiology 2019;35:1228-40. [DOI: 10.1016/j.cjca.2019.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Wald R, Dorian P, Harel Z. Benefits and Risks of Anticoagulation in Dialysis Patients With Nonvalvular Atrial Fibrillation: Navigating Through Darkness. J Am Coll Cardiol 2020;75:286-8. [PMID: 31976866 DOI: 10.1016/j.jacc.2019.11.033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Voukalis C, Lip GY. Atrial Fibrillation and End Stage Renal Failure in Patients Receiving Dialysis: Balancing the Risks and Benefits of Stroke Prevention. Canadian Journal of Cardiology 2017;33:705-7. [DOI: 10.1016/j.cjca.2017.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
13 Zaman JAB, Bhandari AK. Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 2019;24:499-508. [PMID: 31284744 DOI: 10.1177/1074248419858116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Goel N, Jain D, Haddad DB, Shanbhogue D. Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences. J Stroke 2020;22:306-16. [PMID: 33053946 DOI: 10.5853/jos.2020.01886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Garlo KG, Steele DJR, Nigwekar SU, Chan KE. Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. Clin J Am Soc Nephrol 2019;14:125-36. [PMID: 30593489 DOI: 10.2215/CJN.06430518] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Huang ST, Yu TM, Ke TY, Wu MJ, Chuang YW, Li CY, Chiu CW, Lin CL, Liang WM, Chou TC, Kao CH. Syncope and Collapse Are Associated with an Increased Risk of Cardiovascular Disease and Mortality in Patients Undergoing Dialysis. Int J Environ Res Public Health 2018;15:E2082. [PMID: 30248947 DOI: 10.3390/ijerph15102082] [Reference Citation Analysis]
17 Königsbrügge O, Ay C. Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. Res Pract Thromb Haemost 2019;3:578-88. [PMID: 31624777 DOI: 10.1002/rth2.12250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
18 Gullón A, Sánchez Fuentes D, López-de-sá E, Martí-almor J, Barón-esquivias G, Jiménez López J, del Mar Contreras Muruaga M, Suárez Fernández C. Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular. Medicina Clínica 2018;150:8-24. [DOI: 10.1016/s0025-7753(18)30666-3] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ashley J, Mcarthur E, Bota S, Harel Z, Battistella M, Molnar AO, Jun M, Badve SV, Garg AX, Manuel D, Tanuseputro P, Wells P, Mavrakanas T, Rhodes E, Sood MM. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. American Journal of Kidney Diseases 2020;76:311-20. [DOI: 10.1053/j.ajkd.2020.02.446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
20 Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F, Ortiz A, Sarafidis P, Ekart R, Dagres N. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. EP Europace 2020;22:496-505. [DOI: 10.1093/europace/euz358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
21 Yamada SI, Hasegawa T, Soutome S, Yoshimura H, Miyakoshi M, Ueda N, Okamoto K, Hishida S, Rokutanda S, Nakahara H, Fujita S, Akashi M, Kitagawa Y, Kirita T, Shibuya Y, Umeda M, Kurita H. Prevalence of and risk factors for postoperative hemorrhage after lower third molar extraction on warfarin therapy: a multicenter retrospective study in Japan. Odontology 2020;108:462-9. [PMID: 31705338 DOI: 10.1007/s10266-019-00474-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Abuhasira R, Mizrakli Y, Shimony A, Novack V, Shnaider A, Haviv YS. Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis. Sci Rep 2018;8:2976. [PMID: 29445225 DOI: 10.1038/s41598-018-21229-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Defoe K, Wichart J, Leung K. Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation. Can J Kidney Health Dis 2021;8:20543581211046079. [PMID: 34552757 DOI: 10.1177/20543581211046079] [Reference Citation Analysis]
24 Zhao L, Wang WYS, Yang X. Anticoagulation in atrial fibrillation with heart failure. Heart Fail Rev 2018;23:563-71. [PMID: 29569146 DOI: 10.1007/s10741-018-9693-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mahmood M, Lip GYH. Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. Rev Esp Cardiol (Engl Ed) 2018;71:847-55. [PMID: 29958809 DOI: 10.1016/j.rec.2018.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Zhang Y, Yuan YQ. Value of left atrial diameter with CHA2DS2-VASc score in predicting left atrial/left atrial appendage thrombosis in non-valvular atrial fibrillation. Arq Bras Cardiol 2021;116:325-31. [PMID: 33470330 DOI: 10.36660/abc.20190492] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, Wong CX, Sarnak M, Cheung M, Herzog CA, Johansen KL, Reinecke H, Sood MM. Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. Stroke 2021;52:e328-46. [PMID: 34078109 DOI: 10.1161/STROKEAHA.120.029680] [Reference Citation Analysis]
28 Findlay M, MacIsaac R, MacLeod MJ, Metcalfe W, Sood MM, Traynor JP, Dawson J, Mark PB. The Association of Atrial Fibrillation and Ischemic Stroke in Patients on Hemodialysis: A Competing Risk Analysis. Can J Kidney Health Dis 2019;6:2054358119878719. [PMID: 31632680 DOI: 10.1177/2054358119878719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 Kelly DM, Rothwell PM. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. Kidney Int 2020;97:266-78. [PMID: 31866114 DOI: 10.1016/j.kint.2019.09.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
30 Blum D, Chan CT. Iatrogenesis Imperfecta Medicamentosa: Adverse Drug Events in Dialysis Patients are Associated with Higher Resource Utilization and Mortality. Am J Nephrol 2018;47:438-40. [PMID: 29895031 DOI: 10.1159/000489704] [Reference Citation Analysis]
31 Leonte RM, Lucaci LV, Vlad CE, Florea A, Florea L. Atrial fibrillation, end-stage renal disease and hemorrhagic pleural-pericarditis. Arch Clin Cases 2019;6:103-8. [PMID: 34754917 DOI: 10.22551/2019.25.0604.10162] [Reference Citation Analysis]
32 Mahmood M, Lip GY. Anticoagulantes orales no dependientes de la vitamina K para pacientes con fibrilación auricular e insuficiencia renal grave. Revista Española de Cardiología 2018;71:847-55. [DOI: 10.1016/j.recesp.2018.03.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
33 Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e202175. [PMID: 32250434 DOI: 10.1001/jamanetworkopen.2020.2175] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
34 Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Briasoulis A, Burger A, Bangalore S. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis. Journal of the American College of Cardiology 2020;75:273-85. [DOI: 10.1016/j.jacc.2019.10.059] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 24.0] [Reference Citation Analysis]
35 Altawalbeh SM, Alshogran OY, Smith KJ. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value Health 2018;21:1365-72. [PMID: 30502779 DOI: 10.1016/j.jval.2018.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhang L, Steckman DA, Adelstein EC, Schulman-Marcus J, Loka A, Mathew RO, Venditti FJ, Sidhu MS. Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. Cardiovasc Drugs Ther 2019;33:481-8. [PMID: 31165356 DOI: 10.1007/s10557-019-06885-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
37 Bowie M, Valencia V, Perez-alvarez I, Tran M. Safety analysis of apixaban versus warfarin in patients with advanced kidney disease. J Thromb Thrombolysis 2018;46:246-52. [DOI: 10.1007/s11239-018-1683-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018;154:1121-201. [DOI: 10.1016/j.chest.2018.07.040] [Cited by in Crossref: 397] [Cited by in F6Publishing: 344] [Article Influence: 99.3] [Reference Citation Analysis]